Gao JJ, Osgood CL, Feng Z, Bloomquist EW, et al. FDA Approval Summary: Ribociclib Indicated for Male Patients with Hormone Receptor-Positive, HER2-Negative Advanced or Metastatic Breast Cancer. Clin Cancer Res 2023 Aug 18:CCR-23-1133. doi: 10.1158/1078-0432.CCR-23-1133.
PMID: 37594723